drugset / Trial / NCT02874846

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

NCT02874846

Phase 2 Completed 12 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.

Timeline

Start
2016-07
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Topical